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Abstract
Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1–42 oligomers
is proposed to underlie cognitive decline in Alzheimer’s disease (AD). Alterations in membrane trafficking induced by Abeta
oligomers mediates reduction in neuronal surface receptor expression that is the basis for inhibition of electrophysiological
measures of synaptic plasticity and thus learning and memory. We have utilized phenotypic screens in mature, in vitro
cultures of rat brain cells to identify small molecules which block or prevent the binding and effects of Abeta oligomers.
Synthetic Abeta oligomers bind saturably to a single site on neuronal synapses and induce deficits in membrane trafficking
in neuronal cultures with an EC50 that corresponds to its binding affinity. The therapeutic lead compounds we have found
are pharmacological antagonists of Abeta oligomers, reducing the binding of Abeta oligomers to neurons in vitro,
preventing spine loss in neurons and preventing and treating oligomer-induced deficits in membrane trafficking. These
molecules are highly brain penetrant and prevent and restore cognitive deficits in mouse models of Alzheimer’s disease.
Counter-screening these compounds against a broad panel of potential CNS targets revealed they are highly potent and
specific ligands of the sigma-2/PGRMC1 receptor. Brain concentrations of the compounds corresponding to greater than
80% receptor occupancy at the sigma-2/PGRMC1 receptor restore cognitive function in transgenic hAPP Swe/Ldn mice.
These studies demonstrate that synthetic and human-derived Abeta oligomers act as pharmacologically-behaved ligands at
neuronal receptors - i.e. they exhibit saturable binding to a target, they exert a functional effect related to their binding and
their displacement by small molecule antagonists blocks their functional effect. The first-in-class small molecule receptor
antagonists described here restore memory to normal in multiple AD models and sustain improvement long-term,
representing a novel mechanism of action for disease-modifying Alzheimer’s therapeutics.
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Introduction
Disruption of the associative/dissociative balance in synaptic
plasticity that is the basis of learning and memory begins in Mild
Cognitive Impairment (MCI) and progresses as Alzheimer’s
disease continues. Evidence suggests this cognitive decline is
caused by the accumulation of Abeta 1–42 oligomers in the brains
of these patients [1–6]. Oligomers disrupt this balance by binding
to plasma membrane proteins [7–15], changing intracellular
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calcium levels [11,16–18], inducing tau mislocalization, disrupting
microtubules [17,18], altering membrane trafficking processes and
surface expression levels of critical synaptic ion channels [19–21]
and ultimately causing reversible spine loss in neurons [17,22–25].
These disruptions result in reversible impairment of spatial
memory [26,27], that culminates in anterograde amnesia in the
early stages of Alzheimer’s disease [28–31].
Abeta 1–42 oligomer binding to some but not all neurons [19],
and the reversibility of sublethal oligomer-induced cellular changes
[17,22] indicate that there may be a pharmacological basis for
oligomer-induced synaptotoxicity, however, evidence that oligo-
mers bind specifically and saturably to surface receptors has been
underappreciated. While several cell surface proteins have been
identified as receptors of Abeta oligomers [32], therapeutic ligands
for these receptors have not been demonstrated to be effective in
displacing bound Abeta oligomers. Additionally, there is disagree-
ment over the identity of the form of Abeta oligomer responsible
for human cognitive loss, creating difficulty in extrapolating in
vitro results to in vivo efficacy.
In this study we utilized a phenotypic approach to discover
small molecule drug candidates capable of blocking membrane
trafficking dysfunction and synapse loss in mature primary
hippocampal and cortical cultures caused by multiple forms of
Abeta oligomers. This approach is capable of finding compounds
which work by many different mechanisms, including direct
disruption of Abeta oligomers; inhibition of Abeta oligomer
binding; down-regulating expression of binding sites; or blocking
signal transduction downstream from Abeta binding. We have
found that the assays reliably identify compounds that inhibit
Abeta oligomer binding and improve cognitive function in in vivo
models of Alzheimer’s disease. Active molecules discovered with
this approach can be used to identify and characterize the
receptors that mediate the binding and neuronal actions of Abeta
oligomers. The behaviorally-effective compounds are potent and
specific ligands for the sigma-2/PGRMC1 receptor. These
findings support the idea that soluble Abeta oligomers act as
pharmacological ligands on cellular receptors and can be
antagonized with therapeutic small molecules.
Materials and Methods
Neuronal Cultures
All procedures were approved by the Institutional Animal Care
and Use and Committee at Cognition Therapeutics and were in
compliance with the Office of Laboratory Animal Welfare and the
Guide for the Care and Use of Laboratory Animals, Eighth
Edition.
Sprague-Dawley rats, 18 days pregnant, were euthanized by
CO2 asphyxiation followed by cervical dislocation, and embryos
were removed. Hippocampus and cortical tissue from the embryo
brains were digested in 2.5% Trypsin (Life Technologies) to
dissociate cells. Isolated cells were plated at a density of 4.66104
cells per cm2 in 384-well poly-D Lysine coated plates (Greiner) in
Neurobasal Media (Life Technologies) supplemented with B27
(Life Technologies), Glutamax (Life Technologies) and antibiotics
(penicillin, 50 units/ml and streptomycin 50 mg/ml, Life Tech-
nologies). Cultures were maintained at 37uC in 5% CO2 with
weekly media change for 3 weeks prior to experimentation. These
mixed cultures of hippocampal plus cortical neurons and glia were
used for all of the in vitro experiments described.
Trafficking Assay
Vesicular trafficking was measured using an adaptation of a
method by Liu and Schubert [51]. Neurons were treated with
compounds and/or Abeta oligomer preparations (0.086% DMSO
in culture media) and incubated for 1 to 24 hr at 37uC in 5% CO2.
Tetrazolium salts (3-(4,5-dimethylthiazol-2yl)-2,5diphenyl tetrazo-
lium bromide, Roche Molecular Biochemicals) were added to a
final concentration of 0.75 mM and incubated at 37uC for 60–
90 min. Vesicular formazan remaining in cells was quantified by
absorbance spectrometry (590 nm with 690 nm subtracted)
following extraction with 1.6% Tween-20. All compounds were
tested in quadruplicate wells for each concentration in at least 8
replicate experiments with data from all experiments pooled for
analysis with means 6 S.E.M.
Oligomer Preparations
Synthetic peptide (high concentration). Synthetic human
Abeta 1–42 peptide (California Peptide Inc, catalog number 641-15;
American Peptide Company, catalog number 62-0-80; or University
of Pittsburgh Peptide Core facility, primary sequence DAEFRHDS-
GYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was
treated according to published methods to remove any structural
assemblies that may have formed during the synthesis, isolation and
storage procedures [33,34]. An Abeta monomer film was prepared by
evaporating the 1,1,1,3,3,3,hexafluoro-2-propanol (HFIP) at room
temperature from a solution of 0.253 mg Abeta 1–42 in HFIP at
room temperature for 20 min using N2 gas. The film was then
dissolved in dry DMSO (Sigma-Aldrich Catalog number D2650) and
diluted to 100 mM with cold Basal Media Eagle media (BME, Life
Technologies catalog 21010), followed by incubation at 4uC for 24 hr
to form oligomers. The resulting oligomer preparations were
centrifuged at 16,0006g to pellet any insoluble fibrils and the
supernate was diluted in Neurobasal media prior to addition to
cultures. All studies using synthetic oligomers were performed with
this preparation unless otherwise specified. All lots of Abeta 1–42 are
put through a strict quality control process before being used for
experiments: A) vendor-provided MALDI-TOF spectra is checked
for lack of truncated fragments; B) peptide content is .85%; C)
preparation of oligomers at 100 mM as detailed above does not form
a visible pellet of insoluble fibrils when centrifuged at 16,0006g; D)
no cellular toxicity (as measured by fragmentation or loss of neuronal
nuclei) is seen with 24 hr treatment of cells at concentrations up to
14 mM. For some experiments, peptide comprised of the same amino
acid composition of Abeta 1–42 but in a randomized sequence was
used as a control (‘‘Scrambled Abeta 1–42’’, American Peptide, Inc.
62-0-46B).
Synthetic preparation (low concentration). Abeta 1–42
monomer film was formed from 20 mg synthetic Abeta 1–42 in
HFIP. The film was dissolved in 200 ml DMSO, mixed with 10 ml
PBS and incubated for two hours at room temperature at a final
concentration of 500 nM to form the Abeta 1–42 oligomers.
Oligomerization was stopped by adding 100 mg BSA and the
sample was loaded onto a 250 ml column of Sephadex G-75
equilibrated with MEM containing 2 mg/ml BSA. The column
was eluted with MEM + BSA and the void volume containing high
molecular weight oligomers was collected. Pooled fractions of
interest were concentrated with 100 kDa filters (Amicon Ultra).
The retentate was diluted in PBS and concentrated to a small
volume then rediluted with PBS and re-concentrated using
100 kDa filters. This dilution/re-concentration process was
repeated two additional times to remove residual BSA.
Semi-synthetic oligomers
Whole rat brain was homogenized 1:7 (w/v) in 20 mM Tris-
HCl, 137 mM NaCl, pH 7.6 with 1 mM EDTA and 1 mg/ml
protease inhibitor cocktail (Sigma P8340) and centrifuged at
105,0006g for 1 hour at 4uC. Supernates were immunodepleted
Small Molecule Abeta Antagonists for Alzheimer’s Disease
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using protein-A and protein-G Sepharose (Pierce). Filtrates were
concentrated thirty-fold using Amicon 3 kDa filters. After dilution
to 500 uL in TRIS-buffered saline, Abeta 1–42 monomers were
added to this size excluded homogenate to a final concentration of
50 mM and incubated overnight at 4uC. Abeta oligomers were
immunoprecipitated with 6E10-conjugated agarose columns
overnight at 4uC, washed 3 times with PBS (Pierce) and eluted
using Gentle AG/Ab Elution Buffer (Pierce).
AD patient-derived Abeta
Human AD patient (Braak V/VI) and age-matched control
hippocampal brain specimens with ,24 hour post-mortem
interval were obtained from the Brown Brain Bank. Human brain
samples were obtained at autopsy from cognitively normal age-
matched control and Alzheimer’s disease (AD) patients. In all
cases, consent for possible use in research was obtained from the
next of kin in accordance with protocols approved by the
Lifespan/Rhode Island Hospital Institutional Review Board for
human studies IRB #0083-03. All samples were numbered to
remove identifying personal information prior to their investiga-
tional use.
Human brain tissue was homogenized (Dounce glass homog-
enizer) 1:7 (w/v) in ice cold buffer (20 mM Tris, 137 mM NaCl,
pH 7.6 with 1 mM EDTA and 1 mg/mL protease inhibitor
cocktail Sigma P8340) and then centrifuged at 105,0006g for
1 hour at 4uC. Supernates were then immuno-depleted with
protein-A and protein-G Sepharose (Pierce) and then centrifuged
in Amicon Ultra 100 kDa filters at 14,000 g for 10 minutes at 4uC.
The eluted samples were then concentrated approximately 30-fold
using Amicon 10 kDa filters to obtain the10–100 kDa size-
fractionated oligomers which were then captured on 6E10-
conjugated agarose columns (Pierce NHS-Activated Dry Agarose
Resin, catalog # 26196). Immunoisolate material was released
from the 6E10-agarose using gentle elution buffers (Pierce) and
then desalted by repeated washes with PBS in Amicon 10 kDa
MW filters followed by storage in aliquots at 280uC until further
use. Use of brain specimens taken after autopsy meet the criteria
for exemption (Exemption 4) from the requirements in DHHS
regulations (45 CFR 46).
Abeta binding Assay. To assess the ability of test compounds
to prevent the binding of Abeta oligomers, cultures were treated
with compounds for 30 minutes, followed by synthetic Abeta 1–42
oligomer preparation treatment for 60 min (total Abeta concen-
tration 0.5 mM, equivalent to Kd concentration). Alternatively,
displacement of prebound oligomers was evaluated by adding
oligomers 60 min prior to the addition of compounds, followed by
additional 30 minutes incubation. Cells were fixed with 3.75%
formaldehyde for 15 min, blocked with 5% normal goat serum
and 0.5% Triton X-100 and incubated with primary antibodies
for Abeta (1 mg/ml 6E10 or 4G8, Covance catalog numbers SIG-
39320 and SIG-39330, respectively), MAP-2 (0.2 mg/ml Chemi-
con), Synaptophysin-1 (1 mg/ml, Anaspec), glial fibrillary acidic
protein (GFAP, 1 mg/ml, Thermo-Fisher) and fluorescently
labeled secondary antibodies (2 mg/ml, Invitrogen). Images were
acquired on a Cellomics VTi automated microscope with a 20X,
0.75 NA objective and analyzed using ThermoFisher/Cellomics
Neuronal Profiling bioapplication set to measure punctate labeling
of Abeta and synaptophysin-1 along MAP-2 labeled neurites. For
each replicate experiment, at least 100 neurons were sampled from
4 replicate wells for each experimental condition (400 to 500
neurons per experimental condition). The number of replicate
experiments is reported for each experiment. All data presented
for Abeta binding to neurons represents total intensity of Abeta
label in neurite spots per neuron, in relative fluorescent units
(RFU), unless otherwise indicated.
Measurements of Abeta binding to glia were made with a
separate algorithm (ThermoFisher/Cellomics Target Activation
bioapplication) which identifies cells lacking MAP2 labeling. Glial
cells were analyzed after separating them based on their nuclear
morphology as determined by the characteristics of their DAPI
labeling, as described in Fig. S1. All data for Abeta binding to glia
represent total intensity of the Abeta label in the cell body in
relative fluorescent units (RFU), unless otherwise indicated.
Synapse counting assay
Cultures were treated with compounds for 60 minutes prior to
addition of 6 mM (maximum from trafficking dose-response curve)
of synthetic Abeta 1–42 oligomers and incubated for 24 hrs.
Cultures were fixed and immunofluorescently labeled and imaged
as for the Abeta binding assay. The ThermoFisher/Cellomics
Neuronal Profiling bioapplication was used to count synaptophy-
sin-immunopositive puncta along MAP2-labeled neurites. The
number of puncta per unit length of neurites was used to
determine effects of treatments. To attain statistical power of 80%
and a p value of less than 0.05 (determined using G*Power
software [35]), twenty replicate wells were treated per experiment
plate and compared to control wells on the same plate and
experiments were repeated four times.
Behavioral Studies
All procedures were approved by the Institutional Animal Care
and Use and Committee at Columbia University and Stanford
University and were in compliance with the Office of Laboratory
Animal Welfare and the Guide for the Care and Use of
Laboratory Animals, Eighth Edition. Behavioral testing of wild-
type, 3–4 month old, male, C57/BL6 mice, injected bilaterally
into their hippocampus with Abeta oligomers and testing in the
fear conditioning task was done according to published methods
[36]. Animals were anesthetized with 20 mg/kg Avertin prior to
Figure 1. Immunofluorescent labeling of mixed hippocampal/
cortical cultures. A, MAP2 labeled neurons. B, DAPI-labeled nuclei. C,
GFAP labeled glia and Nuclei. D, Merged composite of all three images.
Based on untreated control wells from 104 experimental plates, the
percentage of neurons in the cultures was 26.061.1% (Mean 6 S.E.M.).
Scale bar = 20 microns.
doi:10.1371/journal.pone.0111898.g001
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implantation of cannulas into the hippocampus. Testing of
transgenic hAPP Swedish/London mice in the Morris water
maze or fear conditioning tasks was done according to published
methods [37,38]. To measure brain concentration of drugs, brains
were homogenized in 1 ml PBS per gram of brain tissue using a
handheld homogenizer. Brain homogenate was then extracted
with three volumes of ice cold methanol on ice for 15 minutes and
centrifuged for 15 min. The supernates were analyzed by LC/
MS/MS. Samples were compared to a calibration curve prepared
in a similar manner by spiking blank control homogenate with
standards prepared in DMSO and then extracted as above. At the
end of all behavioral testing, animals were euthanized with CO2
followed by cervical dislocation.
Western Blot Analysis of Abeta Oligomers
Since SDS-containing denaturing gels have been shown to
create artifactual assembly and disassembly products of Abeta
oligomers, non-denaturing conditions were used to characterize
Abeta preparations. Abeta oligomer preparations were run on 4–
15% Tris-HCl nondenaturing gels (BioRad), transferred to
nitrocellulose, probed with 6E10 mouse monoclonal antibody to
Abeta (Covance catalog number SIG-39320) followed by second-
ary goat anti-mouse horse radish peroxidase-conjugated secondary
antibody (Millipore catalog number AP308P) and visualized with
chemiluminescent detection (Immun-Star, BioRad).
Abeta ELISA
Determination of oligomeric and monomeric concentrations of
Abeta contained in a given Abeta preparation was done according
to the method of LeVine [39]. Briefly, total Abeta concentration is
measured by two-site ELISA using different capture (6E10
monoclonal antibody, Covance SIG-39320) and detection (4G8-
conjugated to biotin, Covance, SIG39240) antibodies and
quantifyied with streptavidin-horseradish peroxidase (Millipore
catalog number AP308P). Oligomerized Abeta is measured in the
same samples by a single-site ELISA in which monoclonal
antibodies to the same epitope are used for capture (4G8,
Covance SIG-39330) and detection (4G8-biotin). The 4G8-biotin
cannot bind to captured monomer because the epitope is blocked
by the capture antibody, so only oligomers are detected with this
configuration. The streptavidin-horseradish peroxidase therefore
reports only oligomeric Abeta which has additional exposed 4G8
epitopes. Monomer concentration is calculated as the difference
between total Abeta concentration and oligomer concentration.
Sigma-2 radioligand binding
Radioligand competition assays were performed in membranes
from human Jurkat cells using 5 nM [3H]1,3-di(2-tolyl) guanidine
in the presence of 1 mM (+)-pentazocine with 10 mM haloperidol
to define non-specific binding [40].
Statistical Analysis
For all experiments involving quantification of Abeta immuno-
fluorescent intensity, at least four replicate, multiwell plates were
analyzed, with a minimum of 4 replicate wells per condition on
each plate and 16 fields imaged per well. Averages of total puncta
intensity per neuron (approx. 90 neurons per well) were calculated
for each well analyzed. These well averages were tested for
Figure 2. Characterization of synthetic human Abeta 1–42 oligomers by non-denaturing Western blot, MALDI-TOF. A, Freshly
prepared solutions of synthetic human Abeta 1–42 (lane 1) or 1–40 (lane 3) peptide loaded onto non-denaturing western gels immediately after
reconstitution contain large amounts of monomer (arrow; fainter lower molecular weight band represents peptide degradation product) and little
higher molecular weight material. In contrast, the same solution of Abeta 1–42 peptide that is allowed to oligomerize for 24 hours (lane 2) contains
much larger amounts of higher molecular weight material.50 kDa, and less monomeric protein. The full length of gel lanes are shown from loading
well to dye front. Note that oligomers run differently on non-denaturing gels than globular molecular weight protein size standards [49]. B. The
presence of significant amounts of monomer in oligomer preparations is also confirmed by MALDI-TOF analysis of the same Abeta 1–42 oligomer
preparation that shows both a 4.5 kDa monomer peak and multiple lower abundance peaks corresponding to oligomers of various sizes. MALDI-TOF
(detection range 3–100 kDa) of vehicle (media without Abeta) is shown below for comparison (C).
doi:10.1371/journal.pone.0111898.g002
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normality using a KS distance test before being analyzed for
treatment differences using ANOVA and Bonferroni’s multiple
comparison post-test or pairwise Student’s t-test as indicated
(Graphpad Prism).
Animal Welfare
These studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Use and Care
Committees at Cognition Therapeutics, Columbia University,
Stanford University and QPS Austria GmbH.
Results
In vitro assay system: Mature (21DIV) primary
hippocampal and cortical cultures in 384- well microtiter
plates
We chose to use primary rat neurons grown for at least 21 days
in vitro (21DIV) as a basis for our assays. These neurons express
the full complement of synaptic proteins characteristic of neurons
in the mature brain, and exhibit oscillatory electrical activity in
vitro [41]. Neurons and glia in primary culture have molecular
signaling networks exhibiting excellent registration with intact
brain circuitry, and for this reason have been used for over two
decades as a model system for learning and memory [42,43]. More
complex systems such as acute or organotypic brain slices are very
useful but not amenable to high-throughput screening. Neuronal
cell lines can be used in high-throughput screens, but they do not
replicate the electrophysiological state-dependent signaling of
primary neuronal cultures and are unlikely to adequately model
the subtle alterations in this signaling that are caused by oligomers
during the earliest manifestations of the disease state [44]. For this
reason, primary neuronal cultures are an acceptable compromise
between throughput and fidelity and form the basis for our assays.
These cultures are a mixture of both MAP2-positive neurons and
GFAP-positive glia as characterized with immunofluorescent
labeling (Fig. 1) with 26.061.1% (Mean 6 S.E.M., N=104
experimental plates) of the cells being neurons.
Characterization of Abeta oligomer preparations
The Abeta peptide exists in a variety of structural forms ranging
from monomer, to various shapes and sizes of oligomers, to infinite
polymers known as fibrils. The equilibrium between these different
assembly forms in the human brain and how this equilibrium is
Table 1. Concentration of oligomer and monomer in Abeta preparations as determined by ELISA.
ELISA
Alzheimer’s patient-
derived Abeta
Semi-synthetic
Oligomers
Synthetic Oligomers (low
concentration)
Synthetic Oligomers (high
concentration) Fresh Monomer
Oligomer conc. 137 pM 90.5 nM 65.5 nM 1.5 mM 170 nM
Monomer conc. 0 44.8 nM 0 0.7 mM 2.83 mM
Quantification of relative concentrations of oligomeric and monomeric peptide in a freshly prepared solution of Abeta 1–42 (corresponding to lane 1 in Fig. 2A, 3 mM
total Abeta concentration), Abeta 1–42 oligomers (corresponding to lane 2 in Fig. 2A, 3 mM total Abeta concentration) and Alzheimer’s patient-derived Abeta (Fig. 3)
measured by two-site (total) and single-site (oligomer) ELISA [4,5,39]. Both synthetic peptide solutions contain monomer. In contrast, Abeta peptide immunopurified
from a 1 gram tissue sample of human Alzheimer’s patient hippocampus contains no detectable monomer.
doi:10.1371/journal.pone.0111898.t001
Figure 3. Characterization of human Abeta 1–42 oligomers isolated from patient frozen, unfixed 1 gram brain samples by non-
denaturing Western blot, MALDI-TOF and ELISA. A, Non-denaturing Western blots of immunoprecipitated Alzheimer’s patient hippocampal
samples demonstrates heterogeneous populations of oligomer assemblies. 6E10 antibody labeling of western blots from four different AD patients
(lanes 1–4) detects major bands $250 kDa, and multiple discrete bands between 50–75 kDa. In contrast, APP antibody detects a faint band at
125 kDa (lane 5). Significant amounts of monomeric Abeta 1–42 were not observed in any individual. MALDI-TOF analysis of immune-precipitated
human brain samples demonstrates heterogeneous populations of oligomer assemblies, both between individual Alzheimer’s patients (B, D) and
between age-matched histologically normal individuals (C, E). Significant amounts of monomeric Abeta 1–42 were not observed in any individual.
Albumin was added to samples as an internal size control (arrow in B–E).
doi:10.1371/journal.pone.0111898.g003
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affected in the disease state is currently unknown. Evidence
suggests that threshold concentrations of the water soluble
oligomeric forms of Abeta are the most toxic, and correlate with
disease state [45–47]. Oligomers of various sizes can be seen in
varying amounts when synthetic monomeric Abeta peptide
solutions are allowed to oligomerize, or when Abeta is immuno-
logically isolated from human or transgenic animal brain, with
partial overlap of oligomer sizes in these different preparations
[45,48]. When they have been compared side-by-side in the same
assay [26], all of these oligomers are neuroactive, but have
different potencies. We took a similar comparative approach and
looked for small molecules that were active at stopping the
downstream toxicities of several Abeta oligomer preparations in
vitro. This allowed us to distinguish common pharmacophores
that yielded nodal points of intervention in the signaling cascade.
Synthetic preparations of Abeta oligomers were analyzed on
non-denaturing western gels so that oligomeric forms of Abeta
would not be disrupted. Under these conditions oligomers run
differently on these gels than globular molecular weight protein
size standards [49]. Accordingly, we used several methods to
determine the relative concentrations and apparent molecular
weight size ranges of monomer and oligomer in a given Abeta
oligomer preparation. Oligomer preparations made overnight
from Abeta 1–42 run as a broad band between 75 and 150 kDa
and contain some monomer which runs at 15 kDa (Fig. 2A, lane
2). Fresh preparations of Abeta 1–42 (treated with HFIP to remove
prior structural assemblies), added immediately to the gel run
mostly as monomer but some high molecular weight species still
form quickly (Fig. 2A, lane 1). Fresh preparations of Abeta 1–40
run as monomer with an apparent molecular weight of 15 kDa
with no higher molecular weight assemblies (Fig. 2A, lane 3).
The presence of significant monomer in oligomer preparations is
also confirmed by MALDI-TOF analysis of oligomer preparation
that shows both a 4.5 kDa monomer peak and multiple peaks
corresponding to oligomers (Fig. 2B) while MALDI-TOF analysis
of vehicle without Abeta show only small peaks corresponding to
media proteins (Fig. 2C, [50]). Preparations of oligomeric Abeta
and fresh monomeric Abeta were analyzed using two-site binding
ELISAs which measure total peptide and single-site ELISAs which
Figure 4. Characterization of Membrane Trafficking Assay. Membrane trfficking rate is measured by quantifying the number of intracellular
vesicles labeled with endocytic cargo dye in mature primary hippocampal cultures ($21 DIV). Over time, the dye-filled vesicles (A) are trafficked out
of cells via exocytosis, and the amount of dye in vesicles decreases as it crystalizes on the cell surface as needle-shaped crystals (B). Abeta oligomer
treatment affects the rate of membrane trafficking; 60 minutes following addition of MTT reagent, when vehicle treated neurons (A) still contain
labeled vesicles, Abeta oligomer-treated neurons (B) have already exocytosed labeled vesicles. C. Addition of antibody to Abeta (6E10) to cultures
prevents Abeta oligomers from affecting trafficking rates. Amount of labeled vesicles is quantified (y-axis in D) as a percentage of vehicle-treated
values. D. Concentration-dependent effect of synthetic Abeta oligomer preparation on vesicular labeling relative to vehicle treated cells is blocked by
antibody IgG to Abeta. E. Memantine (MEM), MK-801, and scyllo-inositol were run as controls in the membrane trafficking assay.
doi:10.1371/journal.pone.0111898.g004
Figure 5. Relative potency of Abeta preparations in membrane
trafficking assay. Synthetic human Abeta 1–42 oligomer (high
concentration), freshly made monomer, synthetic oligomers (low
concentration), semi-synthetic oligomers and human Alzheimer’s
patient derived oligomers were dosed in the membrane trafficking
assay. All Abeta preparations alter membrane trafficking rates but with
different EC50 concentrations and different exposure times to Bmax,
similar to literature reports (Table 2).
doi:10.1371/journal.pone.0111898.g005
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determine oligomeric Abeta and allow the total amount of
monomeric Abeta to be estimated [4,5,39]. This analysis shows
that the unfractionated oligomer preparations used typically
contain about 1/3 monomer and that fresh monomer preps
quickly form measurable amounts of oligomer (Table 1).
Non-denaturing Western blots of immunoprecipitated samples
from 1 gram weight frozen unfixed post mortem hippocampus
from Alzheimer’s patients demonstrated heterogeneous popula-
tions of oligomer assemblies (Fig. 3A). Labeling of western blots
from four different AD patients (lanes 1–4) with 6E10 antibody
detects major bands greater than or equal to 250 kDa, and
multiple discrete bands between 50–75 kDa. In contrast, APP
antibody detects a faint band at 125 kDa (lane 5). Significant
amounts of monomeric Abeta 1–42 were not observed in any
individual. MALDI-TOF analysis of immunoprecipitated human
brain samples demonstrates heterogeneous populations of oligo-
mer assemblies, both between individual Alzheimer’s patients
(Fig. 3B, D) and between age-matched histologically normal
individuals (Fig. 3C, E). Significant amounts of monomeric Abeta
1–42 were not observed in any individual. Thus our character-
ization of Alzheimer’s patient brain-derived Abeta supports the
observation that there is overlap in the molecular weight range in
Abeta species seen in synthetic and human-derived oligomer
preps, so that synthetic preps model some aspects of the human
oligomers. It also demonstrates that synthetic Abeta preparations
are a mixture of monomer and oligomeric forms of the protein; the
relative concentration of each depends on the amount of time it is
allowed to assemble.
Characterization of trafficking assay
Since synaptic and memory deficits, rather than widespread cell
death, predominate at the earliest stages of Alzheimer’s disease,
assays that measure these changes are particularly well suited to
discovering small molecule inhibitors of oligomer activity. The
MTT assay is frequently used as a measure of toxicity in cultured
cells, yet we and others have reported that it can also be used to
measure membrane trafficking changes [51–53]. Yellow tetrazo-
lium salts are endocytosed by cells and reduced to insoluble purple
formazan in the endosomal pathway. The level of purple formazan
is a reflection of the number of actively metabolizing cells in
culture, and reduction in the amount of formazan is taken as a
measure of cell death or metabolic toxicity in culture.
We have adapted the exocytosis assay for use with mature
primary neuronal cultures grown for 3 weeks in vitro. When cells
are observed through a microscope approximately 60 min
following the addition of tetrazolium salt, vehicle-treated cells
appear filled with purple formazan-containing vesicles (Fig. 4A),
while cells treated with Abeta oligomers have trafficked these
vesicles to the plasma membrane surface and released their
contents at the cell surface during exocytosis, leading to
precipitation of the water-insoluble dye at the cell membrane
(needle-shaped crystals, Fig. 4B). This decrease can be blocked by
adding stoichiometric amounts of anti-Abeta monoclonal antibody
6E10 to the cultures prior to oligomer addition (Fig. 4C, D) while
antibody alone has no effect on the neurons at low concentrations.
Abeta oligomers accelerate the process of exocytosis, causing a
dose-dependent decrease in the amount of intracellular vesicles
(puncta) filled with reduced purple formazan compared to vehicle-
treated cultures (Fig. 4D, [51]). Under these circumstances, there
is no overall change in the total amount of reduced formazan,
simply a shift in its subcellular location and morphology. We tested
several compounds that have, been reported to block the effects of
Abeta oligomers, including the sugar alcohol scyllo-inositol (AZD-
103), the nAChR antagonist hexamethonium bromide, and the
NMDAR antagonists MK-801 and memantine [21,23,54]; only
memantine was active, weakly blocking oligomer effects at very
high, non-physiological doses above 100 mM (Fig. 4E, [55]).
We have optimized this assay for performance in 384-well
microtiter plates with automated liquid handling robotics for
compound formatting and assay plate stamping. The amount of
labeled vesicles in treated cells is quantified by automated image
processing or by spectrophotometry following extraction from cells
and is calculated as a percentage of vehicle-treated values. Control
wells consist of Abeta and vehicle treatment without test
compounds. We set a passing window for controls (Abeta/vehicle)
of between 50% and 80% with greater than 85% of test runs
passing this criteria, with a resulting z’ score of 0.285 [56]. In the
prevention configuration of this assay, compounds are added to
neuronal cultures first, followed by oligomers. Compounds are also
tested in the treatment configuration of this assay in which
oligomers are added to the cultures first, followed by compound
addition. Compounds active in both assay configurations are more
likely to be intervening at pharmacologically tractable points in the
signaling cascade. Hit compounds that are effective at blocking
Abeta oligomer-induced deficits but do not affect normal
trafficking in the absence of Abeta were forwarded to subsequent
screens.
The potency of Alzheimer’s patient-derived Abeta, synthetic
Abeta oligomer preparations (high concentration oligomers
formed at 100 mM and low concentration oligomers formed at
500 nM) and monomer dosed in the membrane trafficking assay is
shown in Fig. 5 (all concentrations expressed as total Abeta
concentration). The duration of treatment required to achieve
maximal effects on membrane trafficking as well as the EC50
concentrations of each Abeta preparation vary widely, with
Alzheimer’s patient-derived Abeta being several orders of magni-
tude more potent than synthetic Abeta oligomers (Fig. 5,
Table 2). Fresh monomer is the least potent of all preparations,
requiring 24 hours treatment to have any effect on trafficking. The
relatively low potency of synthetic high concentration oligomer
preparations may be partially due to the significant concentrations
of Abeta monomers in these preparations. We have found that
Table 2. EC50 and time to maximum effect of Abeta preparations in membrane trafficking assay.
Membrane Trafficking
Assay
Alzheimer’s patient-
derived Abeta
semi-synthetic
oligomers
Synthetic oligomers (low
concentration)
synthetic oligomers (high
concentration) Fresh monomer
EC50 3.5 pM 5.9 nM 2.7 nM 460 nM 9600 nM
Treatment duration for
maximum response
1 hr 1 hr 1 hr 24 hr 24 hr
EC50 for Alzheimer’s patient derived Abeta, semi-synthetic oligomer, and high concentration synthetic oligomer based on ELISA measurement of Abeta oligomers in the
preparation. EC50 for synthetic oligomer and fresh monomer determined according to total Abeta added to the assay.
doi:10.1371/journal.pone.0111898.t002
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Figure 6. Abeta oligomers bind to a single saturable receptor site on neuronal synaptic puncta. A, B. Abeta 1–42 oligomers bind to
some but not all neurons when added to cultures for 60 minutes (total Abeta concentration = 440 nM, visualized with 6E10 immunolabeling). A
subset of neurons (immunopositive for MAP2, green) exhibit punctate postsynaptic oligomer binding (red) along their neurites; 37%63% of these
puncta colocalize with presynaptic terminals immunolabeled for synaptophysin (C, D). Nuclei (DAPI +, blue) of several non-neuronal cells (glia, MAP2-
negative) exhibit Abeta binding to the cell body. B, F, H. Immunolabeling of Abeta, alone, is shown for clarity. E, F. Fresh Abeta 1–42 monomers,
added to cells with identical concentrations and conditions, is characterized by very low intensity punctate labeling on neurites and labeling of
neuron and glia cell bodies. G, H. 6E10 (monoclonal antibody to Abeta 3–8) added to cultures prior to oligomers blocks binding of Abeta oligomers
to neurite puncta but not to cell bodies of neurons or glia. I. Binding isotherms for Abeta oligomers (red closed circles) and fresh Abeta monomer
(black open circles; treatment for 60 minutes with 44 nM- 14 mM total Abeta concentration) indicate that oligomer binding to neuronal puncta fits a
single-site, saturable model (Kd = 518641 nM, Table 3). Binding of fresh monomer fits a two site model with a high affinity site (412648 nM) and a
second non-saturable binding site. J. Same data as I, expanded to show concentrations used for competition binding studies (440 nM total Abeta
concentration); at these low concentrations binding intensity of oligomers to neuronal synaptic puncta is five-fold higher than with monomer. K, L.
Binding of synthetic Abeta oligomers and fresh monomer to glial cells with round/symmetric nuclear morphology (closed arrowheads in B, F) is not
above background levels (zero Abeta concentration in all graphs). M, N. Binding of synthetic Abeta oligomers and fresh monomer to glia with
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removing monomer from our synthetic prep using size exclusion
chromatography (e.g. the synthetic low concentration oligomer
preps, Fig. 5) yields a preparation that is of intermediate potency
between synthetic high concentration oligomer preps and human
AD patient-derived preparations (Fig. 5). Synthetic high concen-
tration Abeta oligomer preparations contain significant amounts of
monomer when analyzed via western blot (Fig. 2A) or quantified
via two-site and single-site binding ELISAs (Table 1 and
references [5,39]), whereas human AD patient-derived Abeta
does not. Fresh monomer added back into synthetic low
concentration oligomer preparations has been shown to lower
oligomer-induced membrane trafficking deficits [57]. This makes
the testing of fresh monomeric control conditions critical for
proper interpretation of results obtained with any synthetic
oligomer preparations.
Characterization of Abeta oligomer binding to neurons
and glia
We utilized a high content multiparameter automated imaging
assay for measuring both Abeta binding and synapse loss via
immunofluorescence. We characterized the binding of Abeta
oligomers and monomers to neurons and glia in vitro by treating
cultures with Abeta preparations for 1 hour, followed by fixation
and processing for 4G8 immunolocalization. Synthetic Abeta
oligomers exhibit binding to specific postsynaptic sites present on
30–50% of hippocampal neurons in primary cultures (Fig. 6A–D)
as has been reported in the literature [19,58]. This in vitro
observation is similar to the percentage of neurons reported to be
labeled with Abeta oligomers in human AD patient brain [58].
Oligomers also bind to cell bodies of neurons and glia. Freshly
prepared monomeric Abeta binds much less intensely than
oligomers to the same cellular elements (Fig. 6E, F). Co-
treatment of Abeta oligomers with an N-terminal monoclonal
antibody to Abeta (6E10, 26 mg/ml) completely eliminates binding
to synaptic puncta, but cell body labeling of neurons and glia was
still observed (Fig. 6G, H).
Neurons. The binding of synthetic Abeta oligomers to puncta
on neurons is saturable and fits a single site binding model with a
Kd of 512641 nM (mean 6 S.E.M., Fig. 6I, with expanded x-
axis to show lower concentrations used in competition experiments
in Fig. 6J), similar to literature values [9]. In contrast to
oligomers, equal concentrations of fresh monomer results in less
intense punctate binding than that of oligomers (Fig. 6I, J) and
fits a two site binding model, with a high affinity site
(Kd= 4126480 nM) and a low affinity site which is effectively
non-saturable (Kd.1 mM). The high affinity Kd values for
monomer and oligomer binding are not significantly different from
each other, but the monomer binding intensity is 60–70% lower at
each concentration. Whether this high affinity binding actually
represents monomer or small amounts of oligomer that form
during the course of the one hour treatment is not clear; rapid
formation of small amounts of oligomer even in freshly prepared
monomer is apparent from our oligomer-specific ELISA and
Western Blots (Table 1, Fig. 2). The non-saturable monomer
binding may represent fibrils formed from high concentration
monomer nucleated by binding to negatively charged surface
molecules located on the cell body, and subsequent polymerization
[59].
Glia. We rarely observe punctate oligomer binding to glial
cell processes in vitro, whereas glial cell body labeling is common.
The intensity of glial cell body Abeta labeling is bimodal, and
correlates dramatically with nuclear morphology. We observe two
broad categories of DAPI-labeled nuclear morphology in MAP2-
negative glial cells in vitro: round/symmetric nuclei and
condensed/asymmetric nuclei (see Fig. S1; this difference may
result from the serum-free media conditions. Additional charac-
terization of these different glial populations requires further
study). Binding of Abeta oligomers (Fig. 6B, closed arrow) or fresh
monomer (Fig. 6F, closed arrow) to cell bodies of glia with
round/symmetric nuclear morphology is not significantly above
background at any concentration. Bright binding of Abeta
oligomers and monomer to glial cell bodies with condensed/
asymmetric nuclei is more than 10 times as intense, (open arrows
in Fig. 6B, F) and both monomer and oligomer binding to these
cell bodies fits a 2 site binding model with a high affinity site
(oligomer Kd= 2896150 nM, monomer Kd= 4456221 nM) and
a second non-saturable site. (Fig. 6M, N). The high affinity Kd
values for monomer and oligomer binding and the intensity of
binding are not significantly different. This suggests that either 1)
oligomer does not bind to glial cell bodies with asymmetric/
condensed nuclear morphology, or 2) oligomer receptor density is
so low that even the small amount of monomer that oligomerizes
under experimental conditions is able to occupy 100% of available
receptor sites. As with neuronal synaptic puncta, non-saturable
binding to these glial cell bodies may represent polymerization of
monomeric Abeta into fibrils. Binding affinities for oligomers and
monomers to each cell population is summarized in Table 3.
To further demonstrate that the membrane trafficking and
Abeta binding assays are specific for oligomers, we tested
condensed/asymmetric nuclear morphology(open arrowheads in B, F) fits a two site model with a high affinity site (Kd = 2896150 nM) and a second
non-saturating site (Kd.1 M). Scale bars = 20 mm.
doi:10.1371/journal.pone.0111898.g006
Table 3. Binding affinity (Kd) of Abeta preparations to cellular compartments of neurons and glia.
Cell Type NEURONS GLIA
Compartment synaptic puncta
cell bodies with condensed/asymmetric nuclear
morphology
cell bodies with round/symmetric nuclear
morphology
Oligomer Site 1: 518641 nM Site 1: 2896150 nM NS
Site 2: .1 mM
Fresh Site 1: 4126480 nM Site 1: 4456211 nM NS
Monomer Site 2: .1 mM Site 2: .1 mM
Mean Kd 6 S.E.M. Data are results of 13 replicates for oligomer binding and 4 replicates for monomer binding. NS = no significant binding above background.
doi:10.1371/journal.pone.0111898.t003
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preparations of Abeta 1–40 and Abeta 1–42 with a scrambled
amino acid sequence which were prepared by the same method as
for 1–42 oligomers. In both the Abeta binding assay and the
trafficking assay, Abeta 1–40 oligomer preps were less than 200-
fold as potent as Abeta 1–42 (Fig. 7A B), reflecting the lower
amount of oligomer produced with Abeta 1–40 as seen on Western
gels (Fig. 2A). Scrambled Abeta 1–42 had no effect in the
membrane trafficking assay (Fig. 7B). Scrambled peptide is not
recognized by the antibody to Abeta 1–42 and thus its binding to
neurons could not be directly measured.
Evidence from these binding experiments suggests that oligo-
mers behave as a ligand, and bind to a single saturable receptor
site on neuronal synaptic puncta. Because oligomer binding at this
location is associated with the synaptotoxicity underlying Alzhei-
mer’s disease progression, and because oligomer-mediated toxicity
has been shown to be reversible following oligomer washout
[22,60], we focused analysis of subsequent compound-mediated
binding inhibition experiments specifically on oligomer binding at
synaptic puncta, and used oligomer concentrations close to this Kd
for those assay conditions.
Screening for compounds that reverse and prevent
trafficking defects caused by Abeta in vitro
We screened a proprietary library of CNS drug-like small
molecules to identify therapeutic candidates that block Abeta
oligomer-induced vesicle trafficking deficits in mature, primary rat
hippocampal and cortical cultures. Two novel, structurally distinct
active molecules, CT0109 and CT0093, were identified as lead
structures from which other active chemical analogs were
synthesized. The structures of these compounds and of other
chemical analogs of CT0109 – CT01344, CT01346, CT01202
and CT01206 are shown in Fig. 8.
CT0093, CT0109, CT01344 and CT01346 block the oligomer-
induced trafficking deficits in a dose-dependent manner (Fig. 9A–
H, Table 4). These compounds were effective when added either
1 hour prior to or 1 hour after Abeta oligomer preparations
(Fig. 9E–H) showing that they can both prevent and reverse the
effects of Abeta oligomers. When dosed against synthetic
oligomers, ascending concentrations of CT0109, CT0093,
CT01344 and CT01346 cause a progressive rightward shift in
Abeta oligomer EC50 (Fig. 9I–L, Schild slope = 1), indicating
pharmacological competition with oligomers for access to targets
mediating membrane trafficking. CT0109 and CT0093 also cause
a dose-dependent shift in the dose-response effect of human AD
patient-derived Abeta on membrane trafficking (Fig. 9M, N)
without affecting trafficking on their own (Fig. 9O).
Anti-Abeta compounds prevent and reverse binding of
Abeta to neurons, in vitro
We examined whether these compounds could reduce Abeta
oligomer binding to hippocampal/cortical cultures in vitro.
Concentrations in this study represent the maximum dose of the
compound in the membrane trafficking assay (Fig. 9 E–H) and an
Abeta concentration equal to the Ki in the binding assay (Fig. 6).
The addition of 15 mM CT0109, CT0093, CT01344 and
CT01346 one hour prior to addition of synthetic Abeta oligomers
(0.5 mM total Abeta concentration) all prevented the binding of
Abeta oligomers to neuronal cultures by 99%67%, 93%62%,
94%64% and 93%64%, respectively (Fig. 10A–F). When the
same concentration of these compounds were added 1 hour after
addition of oligomers, all four compounds significantly displaced
Abeta oligomers within 1 hour by 44%63%, 4965%, 66614%
and 93613%, respectively (Fig. 10G–L). These compounds
Figure 7. Effect of Abeta control peptides in membrane trafficking assay. Oligomer preparation of Abeta 1–40 is 200 times less potent than
Abeta 1–42 in binding assay (A) and in membrane trafficking (B). Scrambled Abeta 1–42 is not active in the membrane trafficking assay and is not
detectable by the antibody used for the Abeta binding assay.
doi:10.1371/journal.pone.0111898.g007
Figure 8. Chemical structures of compounds.
doi:10.1371/journal.pone.0111898.g008
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displace Abeta in a concentration dependent manner as shown for
CT0093 in prevention (IC50 = 2.2 mM, Fig. 10M) and for
CT01344 in treatment (IC50 = 3.9 mM, Fig. 10N). Compounds
did not reduce the intensity of prebound Abeta oligomers as
completely as they did when added to cultures before the
oligomers. These displacement studies were performed after
1 hour treatment and it is possible that longer treatment with
compounds can achieve a greater level of displacement. However,
incubation with Abeta oligomers for longer times results in
internalization of a portion of the Abeta oligomer labeling
(2768% internalization at 2 hr, Fig. S2), complicating the
quantification of the compound treatment effects. In separate
biochemical assays using an oligomer-specific ELISA, these small
molecules do not appear to directly interact with oligomers and do
not disrupt preformed oligomers or block formation of oligomers
(Fig. 11). Since glial cell body binding at the oligomer concen-
trations used in these compound binding prevention and
displacement experiments is so low (,10% of puncta binding
intensity), we did not analyze the compound’s ability to displace
Abeta binding.
These results demonstrate that these compounds, discovered by
screening for activity in the trafficking assay, are dose-dependent
antagonists of Abeta oligomer binding. This is the first demon-
stration of dose-dependent displacement of Abeta oligomers by a
small molecule.
Figure 9. Abeta 1–42 oligomer-induced trafficking deficits are prevented and competitively inhibited by sigma-2/PGRMC1
antagonists. A, Reduced cargo dye (formazan) labels intracellular vesicles in vehicle-treated cultures, but is trafficked out of the cell more rapidly (B)
following addition of synthetic Abeta oligomers (3 mM, total Abeta concentration). 15 mM CT0109 added 1 hr prior to Abeta restores trafficking to
vehicle-treated levels (C) without affecting vesicles on its own (D). E–H Dose-response curves showing that CT0109 (E), CT0093 (F), CT01344 (G), and
CT01346 (H) restore trafficking deficits whether added before (prevention) or after (treatment) addition of Abeta oligomers. I–L, synthetic Abeta
oligomers exhibit a dose-dependent inhibition of membrane trafficking (red) that is right-shifted 5 to10-fold in the presence of increasing
concentrations of sigma-2/PGRMC1 antagonists (I, CT0109: EC50 = 0.5 mM to 5.3 mM; J, CT0093: EC50 = 0.81 mM to 12.8 mM; K,CT01344: EC50 = 1.7 mM
to 7.1 mM; L, CT01346 EC50 = 5.7 mM to 12.2 mM), consistent with pharmacological competition between compounds and Abeta oligomers. M, N,
Abeta oligomers isolated from human postmortem AD patients exhibits a more potent dose-dependent inhibition of membrane trafficking (red), yet
the same compounds inhibit the maximum effect of oligomers by 60 to 99% (P,0.025, t-test) making these oligomers less efficacious and therefore
less toxic. O, CT0109 and CT0093 (0.2 mM, grey and black filled bars) reverse the trafficking deficit cause by human patient derived Abeta (1.5 pM, red
bar) without affecting trafficking on their own (gray and black open bars).
doi:10.1371/journal.pone.0111898.g009
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Anti-Abeta compounds prevent Abeta-induced synapse
loss in vitro
In addition to altering rates of membrane trafficking, oligomers
have been shown to induce reversible spine retraction in vitro [22]
and to cause a corresponding loss of synapses and synaptic
proteins including synaptophysin [21,47]. Addition of synthetic
Abeta oligomers to neuronal cultures caused an 18% loss of
synaptophysin-immunoreactive puncta in vitro (Fig. 12A,C)
compared to vehicle treatment; this is similar to the degree of
synapse loss seen using ultrastructural stereology methods in post-
mortem hippocampus from humans diagnosed with Mild Cogni-
tive Impairment [61]. Small molecule anti-Abeta compounds
eliminate oligomer-induced loss of synaptophysin-positive puncta
(Fig. 12B, C), with no effect on puncta number when dosed
alone.
Anti-Abeta compounds are effective in vivo
The compounds that were found in our in vitro screens are all
brain penetrant, reaching appreciable concentration in the brain
as evidenced by measurements made 24 hours after dosing in mice
or rats (Table 5). Oligomers cause memory loss when adminis-
tered acutely to rodents [26,62] or as a result of age-dependent
oligomer accumulation in transgenic animals [31,63]. Compounds
did not affect motor activity measured following acute (Fig. 13A,
contextual fear conditioning task training baseline) or long-term
administration (Morris water maze swim speed, data not shown).
Abeta oligomers cause a deficit in contextual fear conditioning-
dependent associative memory when injected directly into the
dorsal hippocampi of wild-type, male C57/BL6 mice 24 hours
prior to testing [62] (Fig. 13B, red bar, p = 0.01, pairwise
Student’s t-test Abeta vs. vehicle, blue bar). CT0109 and
CT0093 (2 mM) injected one hour prior to oligomer injection
completely prevented fear memory deficits (Fig. 13B, filled black
and gray bars, CT0109 p= 0.03, CT0093, p= 0.05, Student’s t-
test comparing Abeta vs. Abeta + compound conditions), but have
no effect on memory when administered alone (Fig. 13B, open
black and gray bars). Two additional compounds which were
active in the membrane trafficking assay, CT01202 and CT01206
(Fig. 8, Table 4), were not effective in preventing memory
deficits caused by Abeta oligomers (Fig. 13B, filled orange and
green bars). These compounds were neuroactive, causing memory
loss when injected alone without Abeta (Fig. 13B, open orange
and green bars). These compounds also affect synapse number
when dosed in the absence of Abeta oligomers in vitro (Table S1).
Transgenic mice overexpressing the human APP gene with
Swedish and London familial mutations accumulate Abeta in the
brain with age [64] and exhibit age-dependent learning and
memory deficits [37]. Eleven month-old female transgenic mice
exhibit deficits in spatial memory as measured by the Morris water
maze probe trial test. Non-transgenic vehicle-treated animals
spend significantly more time in the target quadrant compared to
transgenic vehicle-treated animals (Fig. 13C, p = 0.036, pairwise
Student’s t-test). Oral administration of 30 mg/kg/day of
CT01346 to transgenic animals for 42 days significantly improves
spatial memory retrieval performance (p= 0.005 paired Student’s
t-test vs. transgenic vehicle-treated group). Nontransgenic animals
treated with CT01346 behaved similarly to vehicle-treated wild-
type animals (Fig. 13C).
In order to determine if the compound-mediated improvement
in cognitive performance in transgenic animals is sustained,
transgenic 9 month old male mice treated with vehicle, 10 or
30 mg/kg/day of CT01344 or CT01346 for 5.5 months p.o., as
well as non-transgenic vehicle-treated littermates were tested for
contextual fear conditioning memory formation (Fig. 13D).
When the animals were tested for contextual fear memory
24 hours after training, transgenic mice performed significantly
worse compared with the non-transgenic vehicle-treated animals
(Mann-Whitney U test, p = 0.0246). Transgenic animals treated
with 10 and 30 mg/kg/day of CT01344 (p = 0.0237, p = 0.025,
respectively) and 30 mg/kg/day of CT01346 (p= 0.0005) exhib-
ited significantly improved fear memory performance compared to
vehicle-treated transgenic animals (Mann-Whitney U test,
Fig. 13D). Similar weight gain and mortality in treated and
control groups reflect the specific effects of the compound on
Abeta-mediated behavioral deficits. We conclude that these anti-
Abeta antagonists are capable of preventing and reversing
established memory deficits in both sexes in aged transgenic AD
mouse models following systemic long-term administration, and
represent therapeutic disease-modifying candidates for Alzhei-
mer’s disease.
We counter-screened these behaviorally effective molecules in a
panel of 100 targets present in the brain, including major
receptors, ion channels and enzymes which could affect synaptic
plasticity and found that the efficacious small molecules compete
selectively with high affinity for radioligand binding to sigma-2/
Table 4. Potency of compounds in membrane trafficking assay.
Compound ID CT0093 CT0109 CT01344 CT01346 CT01202 CT01206
Prevention
EC50 (mM) 4.9 3.2 8.7 9.4 6.1 4.3
Log EC50 6 SE 25.3160.05 25.4960.9 25.0660.02 25.0360.99 25.1260.38 25.3660.05
Goodness of fit (r2) 0.999 0.999 0.999 0.998 0.998 0.999
N 33 23 9 9 19 16
Treatment
EC50 (mM) 2.0 4.1 7.3 6.4 n.d. n.d.
Log EC50 6 SE 25.7060.13 25.3960.04 25.1960.11 25.0660.02 n.d. n.d.
Goodness of fit (r2) 0.999 0.998 0.998 0.999 n.d. n.d.
N 16 11 6 9 n.d. n.d.
Prevention: compound added 1 hr prior to Abeta oligomers. Treatment: compound added 1 hr after Abeta oligomers. N = number of experimental repeats (four
replicate wells per experiment). n.d. = not determined.
doi:10.1371/journal.pone.0111898.t004
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PGRMC1 receptors [65]. We also measure the brain concentra-
tions of the test compounds in the mouse models. Examination of
the affinities of the compounds indicates that the measured brain
concentrations at doses that restored memory to normal following
chronic administration in transgenic Alzheimer’s mouse models
corresponds to a greater than 80% receptor occupancy (%RO) at
sigma-2/PGRMC1 receptors (Table 5). Brain concentrations
corresponding to 50% receptor occupancy were not effective at
restoring memory, suggesting that the sigma-2/PGRMC1 is the
target for these compounds.
Discussion
This manuscript describes a series of assays for measuring the
effects of multiple preparations of Abeta oligomers in vitro, and
the use of those assays to find small molecule antagonists of Abeta
oligomers that are capable of reversing cognitive defects in mouse
models of Alzheimer’s disease. In primary cultures of rat
hippocampal and cortical neurons 21DIV, these compounds
prevent and displace the binding of Abeta oligomers to neuronal
receptors, prevent and reverse the effects of Abeta oligomers on
membrane trafficking and prevent the loss of synapses caused by
Figure 10. Small molecule therapeutic candidates can prevent or displace Abeta oligomer binding to mature primary hippocampal
and cortical cultures (21DIV). Abeta synthetic oligomers were added to neuronal cultures (0.5 mM total Abeta concentration) for 40 min prior to
(A–F) or following (G–L) addition of compounds and bound Abeta was detected by immunofluorescence. A, G Vehicle controls with no Abeta show
background fluorescence. C, I, 15 mM CT0109, D, J, CT0093, E, K, CT01344, or F, L, CT01346 show that immuno-fluorescence for punctate binding of
Abeta oligomers to neurites is blocked by all four compounds. Accompanying MAP2 panel shows similar density of neurons from right-hand side for
each Abeta image. Scale bar = 20 mm. M, Quantification of Abeta immunofluorescence shows that pretreatment with CT0093 prevents Abeta
binding in a dose-dependent manner fitting a single site binding model (r2 = 0.79, N= 8, EC50 = 2.262.4 mM). N, CT01344 displaces pre-bound Abeta
binding in a dose-dependent manner fitting a single site binding model (r2 = 0.92, N = 8, EC50 = 3.961.8 mM). * = statistically different than control,
P,0.05, Student’s t-test.
doi:10.1371/journal.pone.0111898.g010
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Abeta. Activity of compounds in these in vitro assays was
predictive for behavioral efficacy in vivo (Table S1).
The current studies provide evidence that synthetic and human-
derived Abeta oligomers act as pharmacologically-behaved ligands
at neuronal receptors, i.e. they exhibit saturable specific binding to
a target, they exert a functional effect related to their binding and
their displacement by small molecule antagonists blocks their
functional effect. The first-in-class small molecule receptor
antagonists described here restore memory to normal in multiple
AD models and sustain improvement long-term. These com-
pounds represent a novel mechanism of action for disease-
modifying Alzheimer’s therapeutics.
Evidence suggests that Abeta oligomers reduce neuronal surface
receptor expression through changes inmembrane trafficking. These
changes are the basis for oligomer inhibition of electrophysiological
measures of synaptic plasticity (LTP) and thus learning and memory
[20,66].Measuring changes inmembrane trafficking rate induced by
oligomers using morphological shifts in formazan has been used in
cell lines to discover Abeta oligomer-blocking drugs [51,52,67–69]
which lower Abeta brain levels in rodents in vivo [70]. Liu and
Schubert [51] discovered that cells respond to sublethal concentra-
tions of Abeta oligomers by selectively accelerating the exocytosis
rate of reduced formazan, while leaving endocytosis rate unaffected.
We and others have found that this assay is sensitive to low levels of
oligomers that do not cause cell death [52,68]. The dual applicability
of this assay to measure both cell death and membrane trafficking
rate under different conditions has led to some confusion in the
literature [71], particularly since low amounts of oligomers that lead
to inhibition of LTP do not lead to cell death [72]. All of our assays
are conducted with non-lethal concentrations of Abeta oligomers.
There are large differences in the potency of synthetic Abeta
oligomers and human derived Abeta in the trafficking assay,
perhaps due to the presence of large amounts of monomer in
synthetic preps. However, we have found that the ability of
compounds to block the effects of multiple sources of Abeta
oligomers without having effects on their own is predictive for their
Figure 11. Small molecule Abeta binding antagonists do not act directly on Abeta oligomers. An ELISA specific for oligomeric forms of
Abeta 1–42 shows that (A) preformed oligomers are dissociated by 8-OH quinoline but not by CT0109 or CT0093, and; (B) assembly of oligomers are
inhibited by Tween but not by CT0109 or CT0093 at concentration of up to 20 mM for 24 hr, ruling out a direct effect of these compounds on
oligomer assembly or disruption.
doi:10.1371/journal.pone.0111898.g011
Figure 12. Small molecule Abeta binding antagonists prevent Abeta 1–42 oligomer-induced synaptic regression in cultured
neurons. A, Abeta oligomers bound to a subset of neurites (red) reduces synaptophysin-immunoreactive synaptic puncta (green). B, Treatment with
sigma-2/PGRMC1 antagonists reduces oligomer binding and restores normal immunoreactivity for the synaptic marker. C, Oligomers induce an
average 18%62 s.e.m. loss in the number of immunoreactive puncta per micron length of neurite (red bar) compared to vehicle-treated cultures
(blue bar). Treatment of cultures with sigma-2/PGRMC1 antagonists (closed bars) restores synaptophysin immunoreactivity to normal, but has no
effect when antagonists are dosed alone (open bars). *p = 0.05, Student’s paired t-test.
doi:10.1371/journal.pone.0111898.g012
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ability to restore cognitive function in in vivo models of
Alzheimer’s disease caused by age-related increases in Abeta
(Table S1). Thus, although our knowledge of the exact
pathological species of Abeta oligomer is incomplete, by using
multiple assays and multiple preps we have discovered disease-
modifying therapeutic candidates with the potential to modify the
course of the disease.
We have linked this membrane trafficking assay with Abeta
binding and synapse counting assays into a platform for
discovering anti-Abeta drugs which restore cognitive ability in
vivo. The binding of synthetic Abeta oligomers to puncta on
neuronal neurites shows concordance with their functional effect
in altering trafficking rates, with a binding affinity (436667 nM,
Fig. 5) agreeing with an EC50 in the functional assay
(462656 nM, Fig. 6). The concentration of compounds needed
to inhibit binding of Abeta oligomers is in good agreement with
the concentration which inhibits the effects of Abeta oligomers on
membrane trafficking and synapse loss in vitro. For example,
CT01344 blocked the effects of Abeta on membrane trafficking
with an EC50 of 8.760.4 mM (Fig. 9) and displaced Abeta
binding on cultured neurons with an EC50 of 3.961.8 mM
(Fig. 10). CT01344 restored synapse loss induced by Abeta 100%
at 15 mM (Fig. 12) The low dynamic range of synapse loss seen
with the non-lethal concentrations of synthetic oligomers used in
all our experiments makes it difficult to observe a dose-dependent
effect. The concentration of compound used is at the top of the
dose-response curve for CT01344 inhibition of oligomer-induced
membrane trafficking deficits (Fig. 9). Thus, there is a good
correlation between potency of the synthetic Abeta oligomer
preparation in the different in vitro assays as well as a good
correlation with potency of the compounds in those assays.
In behavioral studies in transgenic mice, all four of the
compounds we have studied must reach a brain concentration
that exceeds a theoretical receptor occupancy at sigma-2/
PGRMC1 of greater than 80% to be behaviorally effective
(Table 5). The EC50 for the effects of CT01344 in vitro is nearly
two orders of magnitude above its binding affinity for sigma-2/
PGRMC1 as determined by radioligand binding studies
(4865 nM). This offset between affinity at sigma-2/PGRMC1
could be due to one or more factors: 1) physico-chemical
interactions of the compound such as binding to microtiter plate
plastic, could lower the effective concentration of the compound in
in vitro assays, 2) greater than 95% of sigma-2/PGRMC1
receptors need to be occupied by compound to achieve an effect
on binding and function, or 3) the high concentration of the low
potency synthetic Abeta needed to achieve adequate testing
windows in the in vitro assays. The first possibility likely plays
some role, due to the relative lipophilicity of these compounds – a
property which is desired for compounds to penetrate the blood-
brain barrier. The second possibility indicates that the binding site
of the compounds is not identical to the binding site of Abeta
oligomers but rather, that the compounds act to alter the affinity
or surface expression of the Abeta oligomer binding site and that
multiple drug binding sites must be occupied to block the binding
of Abeta oligomers (i.e., the pharmacological concept of ‘‘spare
receptors’’). The third explanation (that a vast excess of compound
is needed to overcome a vast excess of Abeta oligomers) would be
consistent with a direct competition between the compounds and
Abeta, however, this is unlikely given the compound’s ability to
displace already-bound oligomers (Fig. 10) under non-equilibri-
um conditions. This latter evidence suggests that compound is
modulating the receptor site allosterically to increase Abeta
oligomer off-rate.T
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It is challenging to construct a model of how our compounds
might work to block Abeta oligomer binding and effects in the
absence of precise information about the structure of the Abeta
oligomer ligand. Recent reviews have accurately pointed out that
we lack a complete understanding of the precise structure of the
oligomer ligand [32,73], and it would appear difficult to conduct
drug discovery studies in the absence of this information. This
paper lays out a roadmap by which this may be possible: by
systematically comparing the effects of different kinds of oligomers
on the same assays. In this context, the effective small molecules
themselves become tools that reveal downstream biology common
to a wide range of oligomers (some of which may exist in the brain
as equilibrium mixtures of structures).
The non-biased, phenotypic screens we used for finding
compounds that inhibit the effects of Abeta oligomers in cultured
neurons could have detected compounds working by several
different mechanisms of action, including disruption of oligomers
themselves (oligomer dissociation), interference with Abeta oligo-
mer binding to the surface of neurons, or interference with
signaling mechanisms downstream from the binding of Abeta
Figure 13. Small molecule Abeta binding antagonists improve cognitive deficits in mice. A,B, sigma-2/PGRMC1 antagonists prevent
oligomer-induced contextual fear conditioning memory deficits in C57BL/6 male mice. A. No behavioral deficits are observed during fear
conditioning training with any treatment. B. Testing 24 hours after training reveals that a single injection (2 mM) of Abeta antagonists CT0093 (solid
gray bar) or CT0109 (solid black bar) via bilateral intrahippocampal injection one hour prior to oligomer injection (200 nM) prevents oligomer-
induced fear memory deficits (solid red bar;CT0109: *p = 0.03, CT0093: *p = 0.05, pairwise t-test comparing Abeta vs. Abeta plus compound).
Treatment with compound in the absence of Abeta oligomers does not result in fear memory deficits (open grey and black bars, N = 10–18 animals/
group). Treatment with CT01202 or CT01206 (2 mM) did not prevent Abeta oligomer-induced memory deficits (solid orange and green bars, ns = not
significant by paired t-test comparing Abeta vs. Abeta plus compound, N= 12, 9, respectively) and caused fear memory deficits in the absence of
Abeta (open orange and green bars, *p = 0.05, paired t-test, vehicle, vs compound alone, N= 11, 8 respectively). C. Abeta oligomer antagonists rapidly
improve cognitive deficits in aged transgenic mice. Eleven month old female hAPP Swe/Ldn transgenic or wild-type littermates treated for 42 days
with CT01346 at 30 mg/kg/day p.o. significantly improves transgenic animal spatial memory retrieval performance in Morris water maze probe trial
(**p = 0.005, paired t-test, N = 7–9 animals/group). D. Abeta oligomer antagonists sustain cognitive improvement in aged transgenic mice. Nine
month old male hAPP Swe/Ldn transgenic mice treated for 5.5 months with vehicle or Abeta antagonists CT01344 at 10 and 30 mg/kg/day or
CT01346 at 30 mg/kg/day p.o. significantly improves transgenic animal contextual fear conditioning memory deficits (*p = 0.0237,*p= 0.25,
***p = 0.0005, respectively, Mann Whitney U test, N = 13–15 animals/group).
doi:10.1371/journal.pone.0111898.g013
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oligomers. We have ruled out the direct dissociation of oligomers
or the inhibition of oligomer formation (Fig. 11) and have
identified our active compounds as antagonists of Abeta oligomer
binding.
There are different models which could explain the prevention
and displacement of Abeta binding by small molecules. The small
molecules could bind directly to Abeta receptor protein and
compete for binding at the same site or at a distal site on the same
protein, or the compounds could bind to a protein that is a
modulator of the Abeta receptor protein, affecting the affinity of
that receptor protein for Abeta oligomers.
We observed a progressive rightward shift in the dose-response
curve to synthetic and human-derived Abeta oligomers in the
membrane trafficking assay in the presence of increasing
concentrations of test compounds, suggesting competitive antag-
onism of Abeta oligomers (Fig. 9I–L). However, the trafficking
assay is a functional assay downstream of oligomer binding, in
which allosteric interaction with a binding site for Abeta could
appear to be a competitive interaction. The competition of
compounds versus human derived Abeta appears to affect the
magnitude of the response in addition to the potency (Fig. 9M,
N) of the Abeta. This effect could be a result of a real difference in
coupling efficiency between the human vs. synthetic oligomers and
their receptor targets. Alternatively, this may be an artifact due to
truncation of the top of the dose response curve due to
insufficiently high concentrations of human Abeta. The present
data cannot distinguish between these two possibilities. We
observed both inhibition of binding of Abeta oligomers and
displacement of prebound synthetic Abeta oligomers. The latter
effect was not as complete as the former, which could be a function
of the short time of incubation (1 hr). Examining longer time
points for displacement of Abeta oligomers is problematic in living
cells because a fraction of the Abeta is internalized with longer
incubations (27%68% internalized after 2 hour, Fig. S1). With
long-term treatment (such as was done in the behavioral
experiments, in vivo), the presence of compound likely prevents
the binding of additional Abeta oligomers over a period of time
when any Abeta initially bound has been internalized and
degraded by cells, thus providing long-term effectiveness of the
compounds.
Thus, the present data is consistent either with a model in which
these compounds are binding directly to the receptor for Abeta
oligomers or with a model in which the target for these compounds
is acting to modulate the receptor for Abeta oligomers. Many
candidate oligomer receptors have been proposed [7–9,11–13,15],
but the identity of these putative receptors have not been
accompanied by the discovery of small molecule ligands with the
ability to displace oligomers from their receptors. We have
identified the sigma-2/PGRMC-1 receptor as the molecular target
of these compounds. Further evidence for the role of sigma-2/
PGRMC1 in mediating the binding and effects of Abeta oligomers
is the subject of a separate paper [65].
Regardless of exact mechanism, the present data demonstrate
that Abeta oligomers are specific ligands for cell surface receptors
at synapses showing defined single-site saturable binding that is
associated with down-stream functional effects. We have also
demonstrated that small molecules can be used to antagonize the
binding of Abeta oligomers and to inhibit the down-stream effects
of those oligomers on membrane trafficking and synapse loss.
These same molecules are effective at preventing and reversing
cognitive deficits in two animal models for Alzheimer’s disease in
both genders, following short or long systemic administration
indicating that tolerance to these compounds does not readily
develop. These molecules are the first to be identified as functional
antagonists of Abeta oligomer binding on neuronal cells.
The current studies did not examine the effects of compounds
on Abeta load or accumulation in plaques as it is unlikely that
compounds that block binding of Abeta oligomers will affect those
parameters. A recent study using a TET-off APP overexpressing
mouse model observed cognitive improvement in the absence of
changes in amyloid plaques when the transgenic APP gene was
turned off [74]. This finding supports the hypothesis that blocking
the binding and effects of Abeta oligomers can have a therapeutic
effect in the absence of plaque clearance.
Synaptic plasticity processes underlying learning and memory
are complex, and many receptors participate in a brain circuit
location- and state-dependent manner. Oligomers have been
demonstrated to interact with signaling pathways downstream
from a number of receptors.
AD is one of many proteopathy-related diseases including
Huntington’s disease, Parkinson’s and prion diseases. This report
is the first demonstration that a pathogenic protein assembly,
Abeta 1–42 oligomers, acts as a pharmacologically behaved ligand
at a receptor site on target brain cells and are therapeutically
tractable to inhibition by small molecule antagonists. Oligomers
display saturable binding to localized sites on neurons, and their
binding and downstream synaptotoxic effects can be prevented
and competitively displaced by small molecule therapeutics. This
pharmacological mechanism ensures that these therapeutics will
continue to be effective disease-modifying agents as concentrations
of oligomers rise throughout the disease process. These first-in-
class, highly brain-penetrant, disease-modifying amyloid oligomer
receptor antagonists restore memory to normal in multiple AD
models and sustain improvement long-term. This demonstration,
that there is a pathological protein ligand-receptor interaction
underlying Alzheimer’s disease, and that it can be stopped with
small molecule pharmacology, is good news for patients, for whom
no disease-modifying therapies currently exist.
Supporting Information
Figure S1 Differentiation of glial population by nuclear
morphology. The morphology of MAP-2 negative glial nuclei
labeled with DAPI was analyzed via automated image processing.
A. Nuclear labeling with DAPI for each glial cell is graphed as (A)
total intensity versus average intensity and as (B) variable intensity
versus area. Two broad populations of glial cells are seen: One
population with a round, symmetrical nuclear morphology does
not bind Abeta oligomer or monomer (red circle in A, B, and
images in C), and a second population (black dotted lines in A and
B) characterized by a condensed (blue circle in A, B, and images in
D) or asymmetrical nuclear morphology (green circle in A, B and
images in E) binds Abeta oligomer and monomer on its cell body
with equal brightness. Data from glia in these populations are
analyzed separately for Abeta binding quantified in Figure 6 and
Table 3. Abeta images are from cells treated with 4 mM of
synthetic oligomeric Abeta for 30 min.).
(TIF)
Figure S2 Internalization of Abeta oligomers. After
treatment with Abeta oligomers (1 mM) for 1 hr (A, B) or 2 hr
(C, D), cultures were fixed and immunolabeled for Abeta either in
the presence of 0.05% Triton X-100 to permeabilize cells to
immunoglobulins and measure all Abeta present (A, C) or in the
absence of this detergent (B, D) to detect only Abeta bound at the
cell surface. Control labeling with antibody for MAP2 shows that
this intracellular protein is detectable only in the presence of
detergent (E) and not in its absence (F). G, H, Quantification of
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total Abeta and surface Abeta shows that after 1 hr of exposure,
96%68% S.E.M. of the bound Abeta was at the surface, while
after 2 hrs, 73%63% S.E.M. of the Abeta bound was at the
surface, while 27%68% S.E.M. of the Abeta was internalized.
(TIF)
Table S1 Predictivity of in vitro assays for in vivo
behavioral efficacy.
(DOCX)
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